The Longevity Podcast: Optimizing HealthSpan & MindSpan

Dung Trinh

Welcome to a new era of conversation—where artificial intelligence explores what it means to live longer and better. Created and guided by Dr. Trinh, The Longevity Podcast uses AI hosts to bring scientific discovery, health innovation, and human wisdom together. Through AI-driven discussions inspired by real research and medical insight, each episode reveals practical tools for optimizing your healthspan and mindspan—rooted in science, shaped by compassion. Mind. Body. Spirit.  Powered by Science, Guided by Humanity.

  1. 5 hr ago

    Neurofilament Light Chain And The New Era Of Brain Aging

    Send us Fan Mail What if the clearest signal about your brain’s future isn’t hidden inside an MRI, but floating in your blood right now? We dig into Neurofilament Light Chain (NFL), a nervous system biomarker that behaves like a smoke alarm for ongoing nerve damage and could help shift brain health from reactive to proactive. We anchor the story in a remarkable study of 495 Japanese centenarians followed for up to 17 years. Researchers measured amyloid beta, phosphorylated tau, and NFL, and NFL came out on top for predicting cognitive function and mortality risk. That result forces a bigger rethink: clearing plaques may not be the same thing as slowing structural wear and tear across the brain and spinal cord, which helps explain why some Alzheimer’s drugs show modest cognitive benefits even when they hit their biological target. From there, we break down the actual biology in plain language. Axons are long “cables,” NFL is part of their internal scaffolding, and when those cables degrade, NFL leaks into cerebrospinal fluid and then into the bloodstream. New ultrasensitive blood assays like Quanterix Simoa make it measurable without a spinal tap, opening the door to cheaper, repeatable tracking that can respond in weeks, not years. We also get practical about how to use an NFL blood test wisely: why the trend line matters more than a single number, why you should avoid testing right after intense exercise, how obesity can falsely “lower” NFL via dilution, and which health factors tend to push NFL higher (sleep apnea, hypertension, diabetes, kidney disease, inflammation). We close with where this is heading next: tiered screening and “triggered prevention,” plus the open questions about baselines across different populations. If you found this useful, subscribe, share it with someone who cares about brain health, and leave a review. What would you want to learn from your own NFL trajectory? This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.  Never miss an episode—subscribe on your favorite podcast app!

    24 min

  2. 1 day ago

    How A Shingles Shot Could Cut Dementia Risk

    Send us Fan Mail You’ve heard the standard dementia prevention script: eat well, sleep more, do the puzzles, and hope for good genes. Then a result lands that doesn’t fit the script at all, a routine shingles vaccine associated with a 33% lower risk of dementia in a real-world study of 1.5 million Medicare patients. We dig into what that finding does and does not mean, why it’s so hard to dismiss, and how it compares to the modest wins medicine has chased for decades with expensive Alzheimer’s drugs.  From there, we follow the science into the infection hypothesis and the surprisingly consistent epidemiology linking herpes viruses to cognitive decline. We talk HSV1 in the brain, the APOE4 connection, and the registry data showing dementia risk rising after severe herpes infections and falling with antiviral treatment. Then we flip the usual amyloid story on its head: amyloid plaques may act like an ancient antimicrobial defense, trapping pathogens like a biological cage, helpful in the short term and harmful when chronic reactivation keeps triggering more buildup.  We also tackle the shingles puzzle with bioengineered brain tissue research suggesting shingles-related inflammation can “wake up” dormant HSV1 and spark Alzheimer’s-like changes. We zoom out to other viral evidence like EBV and MS, then bring it home with COVID-19 biomarker and imaging findings while keeping the risk in perspective. Finally, we translate all of this into action: shingles and flu vaccine data, what’s unsettled about COVID vaccination studies, and why an adjuvant called AS01 might be a key clue for immune-driven plaque cleanup. If this reshapes how you think about brain health, subscribe, share this with someone caring for aging parents, and leave a review with your biggest question about vaccines and dementia prevention. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.  Never miss an episode—subscribe on your favorite podcast app!

    22 min

  3. 2 days ago

    Alzheimer’s Is Also A Vascular Disease

    Send us Fan Mail Alzheimer’s has been sold to all of us as a neuron story: plaques, tangles, and brain cells fading away. But the data we walk through here points to a more unsettling possibility that the real tipping point is structural. When the brain’s blood vessels fail, memory can fall apart even faster, and what looks like “classic Alzheimer’s dementia” may actually be a vascular collapse hiding in plain sight. We unpack a large autopsy analysis from the NACC database and use it to zoom in on cerebral amyloid angiopathy (CAA), where amyloid beta doesn’t just sit in brain tissue but builds up inside vessel walls. That shift changes everything. We explain the amyloid overflow hypothesis, how perivascular drainage pathways get overwhelmed with age, and why brittle arteries can set off microinfarcts that quietly sever brain networks over years. We also dig into a key double dissociation: CAA drives cortical microinfarcts, while hypertension-related arteriolosclerosis drives deep subcortical injury, meaning blood pressure control is essential but not the whole answer for Alzheimer’s-related vascular damage. Then we go one layer deeper into genetics and the neurovascular unit. APOE ε4 shows up not only as an amyloid risk factor, but as a threat to blood-brain barrier integrity, letting proteins like fibrinogen leak into the brain and ignite microglia-driven inflammation. Finally, we connect these mechanisms to the new era of anti-amyloid monoclonal antibodies, ARIA risk, and why clearing plaques without accounting for “the state of the pipes” may limit real-world cognitive benefit. If this reframes how you think about Alzheimer’s disease, vascular dementia, CAA, microinfarcts, and precision medicine, subscribe, share this with a friend, and leave a review. What do you think matters more for preventing dementia: removing amyloid or protecting brain blood vessels? This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.  Never miss an episode—subscribe on your favorite podcast app!

    20 min

  4. 3 days ago

    Alzheimer’s Breakthrough Meets The Budget Wall

    Send us Fan Mail A medical breakthrough can still fail at the pharmacy counter. We finally have amyloid-targeting drugs for early-stage Alzheimer’s disease, and they are already on the market, but several major health systems have looked at the same evidence and refused to pay. That contradiction is the mystery we unpack, using the explosive Glasgow IPCAD meeting as our guide to what’s really blocking access. We dig into the three barriers driving negative reimbursement decisions: headline drug prices, serious safety risks that require ongoing MRI monitoring, and the hardest problem of all, long-term efficacy. When trials last about 18 months, payers are forced to guess whether small changes in cognitive scores translate into years of real independence. From there, we explore the new toolkit health economists are building, including AI-supported micro-simulation models that create thousands of virtual patients and project outcomes decades into the future. The conversation turns practical fast. We explain why caregiver burden and caregiver quality of life can change the math, why biomarker diagnostics like PET scans and lumbar punctures can bankrupt a system before the first dose, and how real-world evidence programs like coverage with evidence development try to balance access with learning. We also look at global registry efforts such as INRAD that standardize data across borders, then confront the uncomfortable truth: even if the money shows up, many countries lack the infusion clinics, diagnostic capacity, and specialist workforce to deliver these therapies at scale. We close with a provocative question about the near future of blood-based screening and presymptomatic diagnosis, and what it means to know you’re at risk while treatment remains financially out of reach. If this helped you think differently about Alzheimer’s policy, health economics, and brain health, subscribe, share the episode, and leave a review so more people can find it. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.  Never miss an episode—subscribe on your favorite podcast app!

    20 min

  5. 4 days ago

    Your Body’s Real Age

    Send us Fan Mail A camera watches you walk across a room and can estimate your biological age. That sounds like science fiction until you see the data and the logic behind it. We break down a 2026 multidimensional modeling study that replaces the idea of “age as a number” with age as measurable wear and tear across your body and brain, using tools that are surprisingly practical: a marker-free 3D gait camera, a VR eye-tracking test, a soft fNIRS cap for brain connectivity, and a simple blood draw. We start with gait analysis and the overlooked detail that matters more than speed: stride length. A shorter stride can be a clean signal of declining stability, joint flexibility, muscle power, and neuromuscular coordination. Then we move to eye movements, where pro-saccade reaction time becomes one of the strongest single predictors of aging, while smooth pursuit can stay stable thanks to compensatory plasticity. From there, we go under the hood with functional near-infrared spectroscopy to map resting-state functional connectivity, spotlighting Brodmann Area 10 (BA10) and why changes in this “conductor” region may show up as slower adaptation and harder multitasking. Finally, we hit the molecular layer with two neurodegenerative biomarkers: GFAP and NFL. The pattern is nuanced and hopeful, pointing toward chronic low-grade inflammation (“inflammaging”) without implying that healthy aging automatically equals active neuronal destruction. When all four domains are combined with machine learning (XGBoost), the multimodal biological age clock becomes dramatically more accurate than many DNA methylation clocks, reinforcing a core lesson from longevity research: aging is never just one system. If this kind of non-invasive biological age testing becomes common, smart homes and everyday headsets could turn into ambient health monitoring tools, raising big questions about privacy and data security alongside huge opportunities for preventive care. Subscribe for more deep dives, share this with someone who cares about aging well, and leave a review telling us which signal you trust most: gait, eyes, brain connectivity, or blood. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.  Never miss an episode—subscribe on your favorite podcast app!

    24 min

  6. 5 days ago

    Depression Or Dementia First

    Send us Fan Mail Depression and dementia get talked about like two separate problems, until you ask the uncomfortable question: which one comes first? We dig into a huge 22-year longitudinal study (over 13,000 Americans in the Health and Retirement Study) to figure out whether depressive symptoms are a modifiable dementia risk factor or an early clinical warning sign of Alzheimer’s disease and related neurodegenerative pathology. The timeline turns out to be the tell. When depressive symptoms show up in late midlife (ages 50 to 59), dementia risk jumps dramatically, and the relationship holds even after researchers exclude people who develop dementia within the next 5 or 10 years. That pattern fits a long-run “rust” model, where chronic HPA axis activation, cortisol exposure, inflammation, and vascular damage slowly reduce brain resilience and cognitive reserve. When depression appears later (60+), the association fades with lag tests, pointing toward a prodrome like a check engine light rather than decades of wear-and-tear. Then the genetics twist lands: depression predicts incident dementia most strongly in people with lower Alzheimer’s polygenic risk scores, while it barely moves the needle for those with high genetic risk. We also unpack a Markov model of cognitive stages, including the controversial gray zone of subjective memory complaint, and why new depression during that stage can matter so much clinically. If you care about dementia prevention, mental health, or aging well, this conversation gives you a clearer map for action by age and risk profile. Subscribe for more deep dives, share this with someone navigating depression or memory worries, and leave a review with your biggest takeaway. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.  Never miss an episode—subscribe on your favorite podcast app!

    17 min

  7. 6 days ago

    How Diabetes, Cholesterol, And Inactivity Accelerate Hidden Amyloid Plaque

    Send us Fan Mail Think your daily health choices only matter for your heart and waistline? The research we’re unpacking challenges that assumption and makes a sharper, more urgent claim: the same habits may interact with silent Alzheimer’s pathology in your brain years before any symptom shows up. We walk through a major analysis combining the A4 and LEARN cohorts (1,707 cognitively unimpaired adults ages 65 to 85) and explain how PET scans split people into amyloid beta positive and amyloid beta negative groups, then track cognitive change for nearly five years. The headline result is as unsettling as it is actionable. In amyloid negative adults, the measured lifestyle factors don’t significantly predict decline over this window. But for amyloid positive adults, three modifiable factors stand out as accelerants: diabetes (HbA1c ≥ 6.5%), high total cholesterol (≥ 200 mg/dL), and extreme physical inactivity (10 minutes or less of walking per day). We translate the biology into plain English, from insulin resistance starving brain cells and disrupting “cleanup,” to cholesterol reshaping neuron membranes into lipid rafts that trap amyloid, to inactivity shutting down neurotrophic support while inflammation rises. We also put the surprising “null results” in context (why binary alcohol data and one-time baseline snapshots can mislead), highlight education as cognitive reserve that can delay visible impairment, and tackle the biggest twist: the obesity paradox, including why it might reflect leptin-related resilience or reverse causation from early neurodegeneration and unintended weight loss. We end by looking ahead to precision prevention and the coming wave of accurate amyloid blood tests that could make early risk detection far more common. If this changed how you think about dementia risk, subscribe, share the episode with a friend, and leave a review so more people can find it. What habit feels most worth changing if you knew your amyloid status today? This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.  Never miss an episode—subscribe on your favorite podcast app!

    22 min

  8. 20 Jun

    Fish Oil Paradox

    Send us Fan Mail Fish oil has a near-halo status in nutrition culture: a simple, golden capsule that promises better memory, sharper thinking, and protection from cognitive decline. But a landmark longitudinal analysis using ADNI data and published in the Journal of Prevention of Alzheimer’s Disease forces a rethink, suggesting omega-3 supplement use in older adults may be linked to accelerated decline on major cognitive and functional scales. That tension between “common wisdom” and long-term human data is where we start, and we don’t let easy explanations off the hook.  We walk through how the researchers compare supplement users and non-users over a five-year follow-up, why healthy user bias can mislead almost every supplement story, and how propensity score matching creates closer “statistical twins” across age, diagnosis, and APOE ε4 risk. We also tackle the most obvious defense, reverse causality, by looking at pre-supplement trajectories and the timing of decline. Then we quantify what “faster decline” means across MMSE, ADAS-Cog 13, and CDR-SB, translating abstract percentages into real-world loss of memory and independence.  The biggest twist: the decline doesn’t seem to ride on the usual Alzheimer’s markers. Amyloid plaques, tau tangles, and gray matter loss don’t budge. Instead, FDG-PET points to reduced glucose metabolism, an “electrical brownout” where synapses lose energy even when the structure looks intact. From there we explore a plausible mechanism centered on DHA instability, lipid peroxidation, mitochondrial dysfunction, and a self-reinforcing oxidative cycle, plus why supplement quality and oxidation risk may separate “rancid reality” from purified trial products. We close with nuance, including the U-shaped dose-dependent paradox, and a bigger question about oxidizable fats in the modern diet.  Subscribe for more deep dives, share this with a friend who takes fish oil, and leave a review with your take: are supplements helping your brain, or just sounding like they should? This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.  Never miss an episode—subscribe on your favorite podcast app!

    20 min
See All (389)

About

Welcome to a new era of conversation—where artificial intelligence explores what it means to live longer and better. Created and guided by Dr. Trinh, The Longevity Podcast uses AI hosts to bring scientific discovery, health innovation, and human wisdom together. Through AI-driven discussions inspired by real research and medical insight, each episode reveals practical tools for optimizing your healthspan and mindspan—rooted in science, shaped by compassion. Mind. Body. Spirit.  Powered by Science, Guided by Humanity.

Information

  • Creator
    Dung Trinh
  • Years Active
    2021 - 2026
  • Episodes
    389
  • Rating
    Clean
  • Copyright
    © 2026 The Longevity Podcast: Optimizing HealthSpan & MindSpan
  • Show Website
    The Longevity Podcast: Optimizing HealthSpan & MindSpan
  • Provider

You Might Also Like